The abstract is read at the publisher; the summary is JClub's.
Disrupting the mC3 cerulean fluorescent protein sequence in transplantable murine EGFR exon 19 deletion lung cancer cells reduces osimertinib tumor elimination and yields partial drug responses.
- Why it matters: EGFR-mutant lung cancers often respond incompletely to TKIs like osimertinib, and the role of fluorescent-protein–linked immune recognition in murine models is unclear.
- What they did: The authors used CRISPR-Cas9 to delete the mC3 cerulean sequence in established mEGFRdel19 and mEGFR-L860R cell lines, then tested orthotopic tumor formation and osimertinib response in mouse models.
- The result: Two independent mC3-deleted mEGFRdel19 lines formed orthotopic tumors and showed partial osimertinib responses, supporting that mC3-derived epitopes can mediate immunoelimination and improve models for studying incomplete response.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.